GLUE (STOCKS)
Monte Rosa Therapeutics, Inc. Common Stock
$18.550000
-0.410000 (-2.16%)
Prev close: $18.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Markus Warmuth
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,411.25M
- Employees
- 142
- P/E (TTM)
- 62.08
- P/B (TTM)
- 4.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.33 | $-0.38 | +0.0502 | +13.20% |
|
Jun 2025 (Q2)
|
$-0.15 | $-0.39 | +0.2434 | +61.87% |
|
Mar 2025 (Q1)
|
$0.56 | $-0.34 | +0.9037 | +262.93% |
|
Dec 2024 (Q4)
|
$0.23 | $-0.02 | +0.2535 | +1,078.72% |
Financial Statements
| Revenues | $181.54M |
| Benefits Costs and Expenses | $159.58M |
| Costs And Expenses | $159.58M |
| Nonoperating Income/Loss | $13.44M |
| Operating Expenses | $173.03M |
| Research and Development | $138.39M |
| Other Operating Expenses | $34.64M |
| Operating Income/Loss | $8.51M |
| Income/Loss From Continuing Operations After Tax | $20.95M |
| Income/Loss From Continuing Operations Before Tax | $21.95M |
| Income Tax Expense/Benefit | $1.01M |
| Net Income/Loss | $20.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $20.95M |
| Net Income/Loss Available To Common Stockholders, Basic | $20.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Average Shares | 249,469,619 |
| Diluted Average Shares | 250,277,323 |
| Assets | $459.84M |
| Current Assets | $401.82M |
| Cash | $391.30M |
| Other Current Assets | $10.52M |
| Noncurrent Assets | $58.02M |
| Fixed Assets | $27.60M |
| Other Non-current Assets | $30.43M |
| Liabilities | $214.00M |
| Current Liabilities | $61.44M |
| Accounts Payable | $14.51M |
| Wages | $7.26M |
| Other Current Liabilities | $39.67M |
| Noncurrent Liabilities | $152.56M |
| Equity | $245.84M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $245.84M |
| Liabilities And Equity | $459.84M |
| Net Cash Flow From Operating Activities | $149.14M |
| Net Cash Flow From Operating Activities, Continuing | $149.14M |
| Net Cash Flow From Investing Activities | -$67.66M |
| Net Cash Flow From Investing Activities, Continuing | -$67.66M |
| Net Cash Flow From Financing Activities | $1.34M |
| Net Cash Flow From Financing Activities, Continuing | $1.34M |
| Net Cash Flow | $82.81M |
| Net Cash Flow, Continuing | $82.81M |
| Comprehensive Income/Loss | $20.04M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $20.02M |
| Other Comprehensive Income/Loss | -$26.76M |